Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

With insomnia, the figures are staggering: nearly one-third of Americans experience some level of sleep disruption, and for ...

A new study indicates that the drug suvorexant could reduce proteins associated with Alzheimer's by improving sleep quality.

If drugs could be developed to prevent orexin from binding to its receptors, Mignot thought, then people with insomnia would become “narcoleptic for one night”. In 2007, researchers at the ...

Suvorexant belongs to a new class of sleep medications called dual orexin receptor antagonists. Orexin is a molecule that promotes wakefulness; suvorexant blocks it, promoting deeper sleep.

Eisai has launched its insomnia drug Dayvigo in Japan ... Dayvigo (lemborexant) is a dual orexin 1 and 2 receptor antagonist (DORA), a class which is billed as having fewer “morning-after ...

They found that higher levels of both insomnia symptoms and sleep medication use were associated with higher risk of disability a year later. The work is published in the journal SLEEP.

But the study of adolescents in the US also showed that even ... Insomnia and Sleep Medication Use Connected to Disability in Older Adults Apr. 18, 2025 — For adults over the age of 65 ...

But the study of adolescents in the US also showed that even ... Insomnia and Sleep Medication Use Connected to Disability in Older Adults Apr. 18, 2025 — For adults over the age of 65 ...

More symptoms of insomnia and greater use of sleep medication are linked to a higher risk of disability a year later in older adults. The corresponding study was published in Sleep. Evidence suggests ...

AXS-12, known as reboxetine back when it was available as an antidepressant in the United States, may decrease cataplexy ...